Table 2.
Hemodynamics at rest and during steady state (last 30 s) of exercise
| Control | Drug | P Value | |
|---|---|---|---|
| Baseline forearm vascular conductance, ml·dl−1·min−1·100 mmHg−1 | |||
| SDF | 9.0 ± 2.3 | 13.5 ± 3.1 | 0.005 |
| l-NMMA | 6.5 ± 0.6 | 5.1 ± 0.6 | 0.022 |
| SDF + l-NMMA | 10.6 ± 2.2 | 6.2 ± 1.0 | 0.082 |
| Steady-state forearm vascular conductance, ml·dl−1·min−1·100 mmHg−1 | |||
| SDF | 29.1 ± 2.5 | 34.5 ± 4.8 | 0.008 |
| l-NMMA | 22.6 ± 1.9 | 18.9 ± 1.1 | 0.015 |
| SDF + l-NMMA | 33.7 ± 5.8 | 28.9 ± 6.0 | 0.467 |
| Δ Forearm vascular conductance, ml·dl−1·min−1·100 mmHg−1 | |||
| SDF | 20.1 ± 2.6 | 21.1 ± 3.1 | 0.461 |
| l-NMMA | 16.1 ± 1.9 | 13.8 ± 1.2 | 0.049 |
| SDF + l-NMMA | 23.1 ± 4.1 | 22.7 ± 5.6 | 0.936 |
| Baseline forearm blood flow, ml·dl−1·min−1 | |||
| SDF | 7.8 ± 1.9 | 11.3 ± 2.2 | 0.003 |
| l-NMMA | 6.5 ± 0.7 | 5.0 ± 0.5 | 0.005 |
| SDF + l-NMMA | 10.0 ± 2.1 | 5.9 ± 1.0 | 0.030 |
| Steady-state forearm blood flow, ml·dl−1·min−1 | |||
| SDF | 26.3 ± 3.8 | 30.9 ± 4.3 | 0.004 |
| l-NMMA | 20.8 ± 1.7 | 17.6 ± 0.9 | 0.006 |
| SDF + l-NMMA | 31.7 ± 4.3 | 27.4 ± 4.9 | 0.390 |
| Δ Forearm blood flow, ml·dl−1·min−1 | |||
| SDF | 18.5 ± 2.6 | 19.6 ± 3.0 | 0.200 |
| l-NMMA | 14.3 ± 1.7 | 12.6 ± 0.9 | 0.100 |
| SDF + l-NMMA | 21.1 ± 4.1 | 21.7 ± 4.5 | 0.900 |
Data are reported as means ± SE. The effect of drug assessed by Wilcoxon signed rank test. Boldface values indicate statistical significance, drug vs. control. Data reported previously (30).